hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06342986, orgStudyIdInfo id: 2023LS185, secondaryIdInfos id: P01CA111412, type: NIH, link: https://reporter.nih.gov/quickSearch/P01CA111412, briefTitle: Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08-01, primaryCompletionDateStruct date: 2028-06-30, completionDateStruct date: 2029-06-30, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Masonic Cancer Center, University of Minnesota, class: OTHER, collaborators name: National Cancer Institute (NCI), descriptionModule briefSummary: This is a single center Phase I clinical trial of FT536 administered intraperitoneally (IP) 3 times a week for one week for the treatment of recurrent gynecologic cancers. A short course of outpatient lymphodepleting chemotherapy is given prior to the first dose of FT536 to promote adoptive transfer., conditionsModule conditions: Gynecologic Cancer, conditions: Ovarian Cancer, conditions: Fallopian Tube Cancer, conditions: Primary Peritoneal Cavity Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, interventionModelDescription: A minimum of 28 days must separate each Dose Cohort. A minimum of 30 days must separate the 1st and 2nd patient. All patients are assessed for Dose Limiting Toxicity (DLT), primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 33, type: ESTIMATED, armsInterventionsModule interventions name: FT536, interventions name: Fludarabine, interventions name: CY, outcomesModule primaryOutcomes measure: Progression free survival (PFS), secondaryOutcomes measure: Progression free survival (PFS), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Overall survival (OS), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06342973, orgStudyIdInfo id: 5591, briefTitle: Horizontal Ridge Augmentation With Demineralized Bone Allograft Layered With Xenograft - a Case Series, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-27, primaryCompletionDateStruct date: 2025-05-30, completionDateStruct date: 2025-05-30, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Louisiana State University Health Sciences Center in New Orleans, class: OTHER, descriptionModule briefSummary: The aim of this case series is to evaluate the outcomes of horizontal ridge augmentation performed using a combination of demineralized freeze-dried bone allograft layered with xenograft bone with a resorbable native collagen membrane., conditionsModule conditions: Alveolar Ridge Deficiency, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Single group, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 15, type: ESTIMATED, armsInterventionsModule interventions name: Xenograft and allograft, outcomesModule primaryOutcomes measure: Horizontal bone gain, primaryOutcomes measure: Vital bone percentage, primaryOutcomes measure: Bone shrinkage, secondaryOutcomes measure: Surgical complications, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: LSUHSC School of Dentistry, status: RECRUITING, city: New Orleans, state: Louisiana, zip: 70119, country: United States, contacts name: Eswar Kandaswamy, role: CONTACT, phone: 504-941-8272, email: ekanda@lsuhsc.edu, contacts name: Eswar Kandaswamy, BDS, MS, role: PRINCIPAL_INVESTIGATOR, contacts name: Vinayak Joshi, BDS, MS, PhD, role: SUB_INVESTIGATOR, contacts name: Jeanne St Germain, RDH, role: SUB_INVESTIGATOR, geoPoint lat: 29.95465, lon: -90.07507, hasResults: False
protocolSection identificationModule nctId: NCT06342960, orgStudyIdInfo id: KYV101-003, briefTitle: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis (KYSA-3), statusModule overallStatus: RECRUITING, startDateStruct date: 2022-12-01, primaryCompletionDateStruct date: 2028-10, completionDateStruct date: 2029-01, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Kyverna Therapeutics, class: INDUSTRY, descriptionModule briefSummary: A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis, conditionsModule conditions: Lupus Nephritis, conditions: Lupus Nephritis - WHO Class III, conditions: Lupus Nephritis - WHO Class IV, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NA, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 32, type: ESTIMATED, armsInterventionsModule interventions name: KYV-101 anti-CD19 CAR-T cell therapy, interventions name: Standard lymphodepletion regimen, outcomesModule primaryOutcomes measure: Incidence adverse events (AEs) and laboratory abnormalities, primaryOutcomes measure: Frequency of dose limiting toxicities, secondaryOutcomes measure: To characterize the pharmacokinetics (PK), secondaryOutcomes measure: To characterize the pharmacodynamics (PD), secondaryOutcomes measure: To characterize the pharmacodynamics (PD), secondaryOutcomes measure: To evaluate disease related biomarkers, secondaryOutcomes measure: To evaluate disease related biomarkers, secondaryOutcomes measure: To evaluate efficacy, secondaryOutcomes measure: To evaluate efficacy, secondaryOutcomes measure: To evaluate efficacy, secondaryOutcomes measure: To evaluate the immunogenicity (humoral response) of KYV-101, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University Hospital Carl Gustav Carus Dresden, status: RECRUITING, city: Dresden, country: Germany, contacts name: Study Coordinator, role: CONTACT, geoPoint lat: 51.05089, lon: 13.73832, locations facility: University Hospital Erlangen, status: RECRUITING, city: Erlangen, country: Germany, contacts name: Study Coordinator, role: CONTACT, geoPoint lat: 49.59099, lon: 11.00783, locations facility: University Hospital Hamburg-Eppendorf, status: RECRUITING, city: Hamburg, country: Germany, contacts name: Study Coordinator, role: CONTACT, geoPoint lat: 53.57532, lon: 10.01534, hasResults: False
protocolSection identificationModule nctId: NCT06342921, orgStudyIdInfo id: ADC189-2022-01, briefTitle: ADC189 Tablets on Influenza A Virus Infection/Influenza B Virus Infection, acronym: ADC, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-12-07, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2024-06-30, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Jiaxing AnDiCon Biotech Co.,Ltd, class: INDUSTRY, descriptionModule briefSummary: The goal of this Phase II/III study is to investigate the safty and efficacy of ADC189 tablets in adolescents and adults with influenza A virus infection/influenza B virus infection.The main aim to answer:* Phase II study is to evaluate the efficacy of ADC189 tablets in the treatment of adult influenza subjects and determine the optimal therapeutic dose by analyzing the time of virus titer turning to negative. All the results will be used to design the Phase III study.* Phase III study is to evaluate the efficacy of ADC189 tablets by analyzing the duration of remission of all influenza symptoms in adolescents and adults subjects with influenza.Participants will be taken ADC189 teblets/Placebo once, and be observed by 22 days.Phase II study has 3 groups: 15 mg ADC189; 45 mg ADC189; and Placebo; Phase III study has 2 groups: 45 mg ADC189; and Placebo., conditionsModule conditions: Safety Issues, conditions: Effect of Drug, designModule studyType: INTERVENTIONAL, phases: PHASE2, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 675, type: ESTIMATED, armsInterventionsModule interventions name: 15 mg ADC189, interventions name: 45 mg ADC189, interventions name: Placebo, outcomesModule primaryOutcomes measure: the severity of influenza, primaryOutcomes measure: the safety of study drug, eligibilityModule sex: ALL, minimumAge: 12 Years, maximumAge: 65 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Rui Jin Hospital, status: RECRUITING, city: Shanghai, state: Shanghai, country: China, contacts name: Haili Liu, Dr, role: CONTACT, phone: +862134188900, email: rjhfbgs@rjh.com.cn, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06342908, orgStudyIdInfo id: 23-001700, secondaryIdInfos id: NCI-2024-00210, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), briefTitle: A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-08, primaryCompletionDateStruct date: 2027-03-08, completionDateStruct date: 2028-01-09, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Jonsson Comprehensive Cancer Center, class: OTHER, descriptionModule briefSummary: This phase I trial tests the safety and side effects, and best dose of a vaccine (neoantigen-target ppDC) in treating patients with H3 G34-mutant diffuse hemispheric glioma. Vaccines made from the patient's own white blood cells and peptide-pulsed dendritic cells may help the body build an effective immune response to kill tumor cells. Giving neoantigen-targeted ppDC may be safe, tolerable and/or effective in treating patients with diffuse hemispheric glioma with a H3 G34 mutation., conditionsModule conditions: Diffuse Hemispheric Glioma, H3 G34-Mutant, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 6, type: ESTIMATED, armsInterventionsModule interventions name: Biospecimen Collection, interventions name: Dendritic Cell Therapy, interventions name: Leukapheresis, interventions name: Magnetic Resonance Imaging, interventions name: Poly ICLC, outcomesModule primaryOutcomes measure: Incidence of regimen-limiting toxicities, secondaryOutcomes measure: Significant increase in gamma-interferon (IFN) gene expression signature, secondaryOutcomes measure: Significant clonal T cell expansion, secondaryOutcomes measure: Targets of clonal cytotoxic T cell expansion, secondaryOutcomes measure: Pro-inflammatory phenotypic changes in immune cell populations, secondaryOutcomes measure: Changes in immune cell subset expansion and contraction in T cell and myeloid-derived cell populations, secondaryOutcomes measure: Changes of immune cell markers profile in T cell and myeloid-derived cell populations, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: UCLA / Jonsson Comprehensive Cancer Center, city: Los Angeles, state: California, zip: 90095, country: United States, contacts name: Sichen C. Li, role: CONTACT, phone: 310-592-9091, email: sichenli@mednet.ucla.edu, contacts name: Anthony C. Wang, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 34.05223, lon: -118.24368, hasResults: False
protocolSection identificationModule nctId: NCT06342869, orgStudyIdInfo id: 690, briefTitle: Comparison of the Effects of Lidocaine and Articaine Used for Buccal Infiltration and Supplemental Palatinal Infiltration Anesthesia in Teeth With Irreversible Pulpitis, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-04-01, primaryCompletionDateStruct date: 2022-10-01, completionDateStruct date: 2022-12-01, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Akdeniz University, class: OTHER, descriptionModule briefSummary: Objective: The aim of this study was to compare the effects of articaine or lidocaine in buccal infiltration or palatal infiltration in addition to buccal infiltration in maxillary first or second molars with irreversible pulpitis.Method: Among the patients who applied to Akdeniz University Faculty of Dentistry Endodontic Clinic for the treatment of maxillary molars with irreversible pulpitis, 80 volunteers who met the criteria were included in the study. Eighty patients were divided into 4 groups (n = 20). 1. group buccal infiltration with 4% articaine containing 1:100,000 epinephrine, 2. group buccal infiltration with 2% lidocaine containing 80,000 epinephrine, 3. group buccal and palatinal infiltration with 4% articaine containing 1:100,000 epinephrine, 4.group buccal and palatinal infiltration with 2% lidocaine containing 80.000 epinephrine. Pain during the endodontic procedure was determined and recorded according to the Heft Parker visual analog scale., conditionsModule conditions: Fist and Second Molars With ırreversible Pulpitis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 80, type: ACTUAL, armsInterventionsModule interventions name: Anesthesia, outcomesModule primaryOutcomes measure: Assessment of complementary palatinal anesthesia with VAS, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Akdeniz University, city: Antalya, zip: 07070, country: Turkey, geoPoint lat: 36.90812, lon: 30.69556, hasResults: False
protocolSection identificationModule nctId: NCT06342856, orgStudyIdInfo id: idiopathic infertility, briefTitle: Evaluation of Treatment With Coenzyme Q10 and L-Carnitine on Semen Parameters in Infertile Men With Idiopathic Oligoasthenoteratospermia, acronym: infertility, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-06-15, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2024-07-01, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Ain Shams University, class: OTHER, descriptionModule briefSummary: Evaluation of treatment with Coenzyme Q10 and L-Carnitine on Semen Parameters in Infertile men with Idiopathic Oligoasthenoteratospermia, conditionsModule conditions: Infertility Unexplained, conditions: Oligospermia, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: co enzyme Q10, L- Carnitine, outcomesModule primaryOutcomes measure: Changes in Semen analysis parameters compared to baseline, secondaryOutcomes measure: Serum hormone levels ([FSH], [LH], testosterone, and prolactin) levels compared to baseline and Cost analysis, eligibilityModule sex: MALE, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ain Shams University, status: RECRUITING, city: Cairo, zip: 002, country: Egypt, contacts name: ahmed ma maher, lecturer, role: CONTACT, phone: 01013340534, email: drwaleedabdelhamid@gmail.com, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06342830, orgStudyIdInfo id: End 20-05 P, briefTitle: Comparing the Effect of Different Intracanal Dressing on Failed Root Canal Treated Cases on Periapical Healing, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2025-05, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Ain Shams University, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to compare the effects of different intracanal medication between endodontic retreatment visits in previously failed root canal treatment patients (single root canal anteriors or premolars teeth). The main question it aims to answer are:* Is natural and synthetic intracanal Medicament effective in reducing or complete healing of Periapical lesions or not? the researchers will compare the effect of different intracanal dressing including:* nanocurcumin gel* curcumin gel* ciprofloxacin +ibuprofen gel* calcium hydroxide Paste as control group in between the endodontic retreatment visits to see if these medicaments work well on periapical lesion healing this outcome measured by Cone beam CT at base and after 6 months follow up periods, conditionsModule conditions: Periapical Disease, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: nanocurcumin gel, interventions name: Curcumin Gel, interventions name: Ciprofloxacin 500 mg +ibuprofen 400mg, interventions name: Metapaste [calcium hydroxide paste (control group)], outcomesModule primaryOutcomes measure: healing of periapical lesion, secondaryOutcomes measure: antibacterial effect (CFU), secondaryOutcomes measure: Interappointment Pain, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: faculty of dentistry, Ain shams university, city: Cairo, zip: 11512, country: Egypt, contacts name: Rawda Baghdady, role: CONTACT, phone: 01142361074, email: RawdaBaghdady@dent.asu.edu.eg, contacts name: sarah H Fahmy, role: CONTACT, phone: 01005267999, contacts name: Rawda M Baghdady, PHD student, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 30.06263, lon: 31.24967, documentSection largeDocumentModule largeDocs typeAbbrev: Prot_SAP, hasProtocol: True, hasSap: True, hasIcf: False, label: Study Protocol and Statistical Analysis Plan, date: 2020-09-20, uploadDate: 2024-03-01T05:02, filename: Prot_SAP_000.pdf, size: 719008, largeDocs typeAbbrev: ICF, hasProtocol: False, hasSap: False, hasIcf: True, label: Informed Consent Form, date: 2020-09-20, uploadDate: 2024-03-01T05:04, filename: ICF_001.pdf, size: 284949, hasResults: False
protocolSection identificationModule nctId: NCT06342817, orgStudyIdInfo id: UFFS, briefTitle: Effects of Meditation on Sleep Quality of Medical Students, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-18, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2024-06-30, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Universidade Federal da Fronteira Sul, class: OTHER, descriptionModule briefSummary: The objective of the study is to evaluate the effect of an 8-week online mindfulness-based meditation program on quality sleep status of undergraduate students medicine in the city of Passo Fundo/RS and Chapecó/SC In addition to sleep quality, secondary outcomes such as mindfulness, symptoms of depression, stress, anxiety and burnout will also be assessed, conditionsModule conditions: Sleep Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Those students interested in participating in the study will leave their contact details (telephone and email) to the research coordinator, to whom it will be sent an online questionnaire containing the inclusion and exclusion criteria, and the free consent form through the Google forms platform. Collection instruments will only be made available after fulfilling the inclusion criteria and absence of exclusion criteria and agreement with the consent form. Responders will be randomly randomized 1:1 and subsequently communicated whether they will participate in the intervention group or the control group., primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, maskingDescription: Responders will be randomly randomized 1:1 and subsequently communicated whether they will participate in the intervention group or the control group., enrollmentInfo count: 136, type: ESTIMATED, armsInterventionsModule interventions name: online mindfulness based meditation program, outcomesModule primaryOutcomes measure: Change in the quality of sleep of medical students on weeks 5, 9 and 17 by the PSQI and ESE, secondaryOutcomes measure: Change in the awareness of medical students on weeks 5, 9 and 17 by the MAAS, secondaryOutcomes measure: Change in the depression, anxiety and stress symptoms of medical students on weeks 5, 9 and 17 by the DASS-21, secondaryOutcomes measure: Change in the burnout symptoms of medical students on weeks 5, 9 and 17 by CBI-S, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Universidade Federal Da Fronteira Sul, status: RECRUITING, city: Passo Fundo, state: RS, zip: 99010200, country: Brazil, contacts name: Tiago T Simon, MD, role: CONTACT, phone: +5554991843384, email: tiago.teixeira@uffs.edu.br, geoPoint lat: -28.26278, lon: -52.40667, hasResults: False